miriplatin hydrate (miriplatin hydrate / SMP 11355 / Miripla)

✓ Approved

Sumitomo Pharma Co., Ltd. · Small Molecule · Small Molecule

What is miriplatin hydrate?

miriplatin hydrate is a small molecule developed by Sumitomo Pharma Co., Ltd.. It is approved for therapeutic indications via injectable (others) or intraarterial injection.

Drug Profile

Brand Names	miriplatin hydrate, SMP 11355, Miripla
Company	Sumitomo Pharma Co., Ltd.
Drug Class	Small Molecule
Route	Injectable (Others), Intraarterial Injection
Status	Approved

Sources: ClinicalTrials.gov, Sumitomo Pharma Co., Ltd.

Therapeutic Indications

miriplatin hydrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic Area	Condition	Phase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Hepatic cancer	✓ Approved

Related Research Articles

PubMedEnvironmental research2026-10-14

Hemihydrate phosphogypsum as a waste-derived sulfate source for low-carbon supersulfated cement: Hydration regulation and strength-normalized environmental performance.

Sun Zhengning Z, Wang Boxin B, Zuo Yibing Y, Mu Ru R et al.

Hemihydrate phosphogypsum (HPG) can serve as a waste-derived sulfate source in low-clinker supersulfated cement (SSC), expanding phosphogypsum utilization while reducing demand for natural gypsum. This study examines how HPG content governs the temporal evolution of sulfate supply and how this evolution relates to hydration, pore structure, and long-term strength in SSC co-activated with ferroaluminate clinker (FAC), carbide slag (CS), and sodium silicate (SS). Mixtures containing 5-25 wt% HPG were evaluated for compressive strength. The 10, 15, and 20 wt% HPG mixtures were further analyzed by hydration kinetics, pore-solution chemistry, quantitative phase analysis, and microstructural characterization. Composite-activated SSC developed 10.23-14.36 MPa at 1 d, corresponding to a 205.4-328.7% increase over the CS-activated reference. The 15 and 20 wt% HPG mixtures reached 65.54 and 63.76 MPa at 28 d and continued to increase to 81.56 and 78.79 MPa at 270 d, respectively. At 10 wt% HPG, sulfate depletion after early hydration constrained continued ettringite formation and late-age pore refinement. At 20 wt% HPG, sustained reaction of ground granulated blast-furnace slag (GGBS) generated slightly more ettringite and C-(A)-S-H, but a larger fraction of pores >50 nm remained, diminishing the strength efficiency of the additional hydration products. The 15 wt% HPG mixture provided the most favorable coupling of sulfate supply, hydrate accumulation, pore refinement, and strength, and achieved the lowest 28 d energy- and carbon-intensity indices among the investigated mixtures.

PMID 42874899

Read full article →

PubMedFrontiers in pediatrics2026-10-09

Clinical efficacy and safety evaluation of dexmedetomidine hydrochloride nasal spray for sedation before examinations in children aged 2 to 6 years: protocol for a randomized controlled trial.

Wang Xiaoling X, Li Xiong X, Lei Xiaoping X, Dong Wenbin W

Children aged 2 to 6 years are prone to fear and resistance during medical examinations, necessitating sedation assistance. Traditional sedation modalities have limitations such as inconvenient operation, slow onset, or respiratory depression. Dexmedetomidine hydrochloride, a highly selective α₂-adrenergic receptor agonist, exerts sedative, analgesic, and anxiolytic effects with minimal respiratory and circulatory impacts. Its nasal spray is rapidly absorbed via the mucosa, avoiding the first-pass effect, and is thus suitable for young children. This study compares intranasal dexmedetomidine hydrochloride with oral chloral hydrate to evaluate the former's clinical efficacy and safety for pre-examination sedation in young children. This is a single-center, prospective, randomized controlled trial conducted at the Children's Medical Center of the Affiliated Hospital of Southwest Medical University. A total of 248 children aged 2-6 years with ASA physical status I/II requiring sedation for outpatient examinations will be enrolled and randomized 1:1 to receive dexmedetomidine hydrochloride nasal spray (2μg/kg, experimental group) or oral chloral hydrate syrup (50 mg/kg, control group) via computer-generated random sequences. Vital signs will be monitored continuously; sedation onset/duration, MOAA/S (sedation depth), and Steward (recovery status) scores will be recorded. Adverse events will be observed to compare sedation success rates and safety between groups. This study has been approved by the Medical Ethics Committee of the Affiliated Hospital of Southwest Medical University (Approval No. KY2025368). Results will be disseminated via peer-reviewed publications and conference presentations. https://www.chictr.org.cn/showproj.html?proj= 320640, ChiCTR2600126783.

PMID 42851750

Read full article →

PubMedACS omega2026-10-09

From Hydrogen Bond Disruption to Accelerated Polymerization: Atomic Mechanisms of Microwave-Accelerated C-A-S-H Gel Formation.

Duan Luyao L, Zhang Ruochen R, Pan Zhu Z, Ma Guowei G

Although microwave curing accelerates concrete strength development by a significant compared to steam curing, the atomistic origins of this kinetic enhancement remain elusive. Using molecular dynamics simulations, we investigate the influence of microwave irradiation on the nucleation and growth of Calcium-Alumino-Silicate-Hydrate (C-A-S-H) gels. The results show that alternating electric fieldsapplied via intermittent (IM) or sinusoidal (SM) modesinduce intense rotational and translational motion in polar water and hydroxyl groups. The alternating electric field reduces the hydrogen bond retention ratio from 0.915 in the Control group to 0.827 under SM mode and 0.725 under IM mode. Cage-jump dynamics analysis confirms the resulting "decaging" of monomers, with the non-Gaussian parameter α2(t) rising from 0.33 (Control) to 0.64 (SM) and 0.85 (IM), while the cage residence time τ_cage decreases from 85 ps (Control) to 52 ps (SM) and 38 ps (IM). The released monomers exhibit significantly enhanced mobility, with mean square displacements increasing by 37% under SM mode and 44% under IM mode compared to the Control group.The two microwave modes drive distinct polymerization pathways. The SM mode promotes deep cross-linking into Q 3 (7.0%) and Q 4 (2.4%) structures through continuous energy input. The IM mode accelerates Q 0 consumption (from 75% to 60%) and preferentially forms Q 1 (20.2%) and Q 2 (16.9%) chain-like oligomers through pulsed energy delivery. Correspondingly, Si-O-Si and Si-O-Al bond counts increase by 91.2% and 145.4% under SM mode, and by 128.6% and 294.5% under IM mode, respectively. These findings establish a fundamental link between electromagnetic energy input and nanoscale gel assembly, providing a molecular-level rationale for the accelerated strength gain observed in microwave-cured cementitious materials.

PMID 42852208

Read full article →

PubMedFrontiers in physiology2026-10-07

Effects of carbon dioxide hydrate cryotherapy on knee flexor muscle function recovery trajectory after muscle damage: a randomized controlled trial.

Watabe Rina R, Shiozaki Daigo D, Ono Kohei K, Hirata Kosuke K et al.

This study investigated the effects of carbon dioxide hydrate (CDH) cryotherapy on the recovery trajectories of muscle function and physiological markers following exercise-induced muscle damage (EIMD) of the knee flexors. In a randomized parallel-group design, 24 young men were assigned to the CDH, conventional icing (ICE), or non-intervention control (CON) group (n = 8 per group). To induce muscle damage, participants performed 10 sets of eight maximal eccentric contractions of the knee flexors in a prone position (knee joint range: 75°-15° of flexion at 60°/s; 0° = the fully extended anatomical position). Maximal voluntary isometric contraction (MVIC) torque of the knee flexors was measured at 30° of knee flexion at baseline (PRE), immediately post-exercise (POST), and at 4.5, 24, 48, 72, and 168 h post-exercise. Secondary outcomes, including thigh circumference, hip joint range of motion (ROM), and hamstring muscle stiffness and pressure-induced soreness were assessed at all time points except POST. A 20-min intervention was administered after each assessment from POST to 72 h. Linear mixed-effects models, adjusted for PRE values, revealed no significant group × time interactions for changes from PRE in any outcome across post-exercise time points (POST to 168 h for MVIC torque; 4.5 to 168 h for secondary outcomes; p = 0.177-0.914). A significant main effect of group was observed only for hip joint ROM (p = 0.039). Post-hoc comparisons revealed a significantly greater overall reduction from PRE in the CDH group than in the CON group (difference: 10.3°, 95% CI: 3.0° to 17.6°, p = 0.017), with no significant differences between the other group pairs (both p = 0.131). Given the multi-outcome testing, this isolated effect should be interpreted as exploratory. Under the present experimental conditions, CDH cryotherapy did not accelerate the recovery of muscle function or attenuate secondary markers following EIMD relative to conventional icing or no intervention.

PMID 42840088

Read full article →

PubMedActa crystallographica. Section E, Crystallographic communications2026-10-06

2,2'-(Ethane-1,2-di-yl)bis-[3-(pyridin-2-yl)imidazo[1,5-a]pyridin-2-ium] dichloride hexa-hydrate.

Vassilyeva Olga Yu OY, Kokozay Vladimir N VN, Goreshnik Evgeny E

The title compound, C26H22N6 2+·2Cl-·6H2O, crystallizes in the monoclinic space group P21/n with one mol-ecule in the asymmetric unit. Structure determination at 150 K from a two-component twin crystal reveals the non-symmetrical n-shaped dication, where two pyridine-imidazole fused cores bearing pendant pyridyl rings are linked by an ethyl-ene bridge. The fused five- and six-membered rings are almost coplanar with the largest deviation from the mean plane being 0.019 Å for a nitro-gen atom of one of the rings. The pendant pyridyl groups are twisted by 42.14 (11) and 46.47 (11)° with respect to the planes of the adjacent imidazo[1,5-a]pyridinium cores. In the crystal, the dications stacked along the b-axis direction are linked by π-π inter-actions that possibly stabilize the n-type structure in the solid state. The chloride anions and water mol-ecules form R 2 4(8), R 5 5(12), R 6 6(12) and R 8 11(22) ring motifs through O-H⋯O/Cl hydrogen bonds, building corrugated layers that run between columns of the stacked organic dications.

PMID 42835851

Read full article →

PubMedActa crystallographica. Section E, Crystallographic communications2026-10-06

Structures of bimetallic FeIII-FeIII and trimetallic FeIII-K-FeIII complexes incorporating the deprotonated ligand N,N'-bis-(2-hy-droxy-3-methoxy-ben-zyl-idene)-1,2-phenyl-enedi-amine.

Thiam Mariama M, Diouf Ngoné N, Orton James J, Ndoye Cheikh C et al.

The title compounds μ-oxido-bis-[(2-{[2-(3-meth-oxy-2-oxido-benzyl-idene-amino)-phenyl-imino]-meth-yl}-6-meth-oxy-phenolato)iron(III)] penta-hydrate, [Fe2(C22H18N2O4]·5H2O or {[(FeIII(L)](μ2-O)[FeIII(L)]}·5H2O (2), and di-chlorido-bis-(μ-2-{[2-(3-meth-oxy-2-oxido-benzyl-idene-amino)-phenyl-imino]-meth-yl}-6-meth-oxy-phenolato)diiron(III)potassium(I) nitrate, [KFe2(C22H18N2O4)2Cl2]NO3 or {[(FeIII(L)(Cl)](K)[FeIII(L)(Cl)]}·NO3 (3), were formed from the reaction of the metallo-ligand [FeII(L)]·(H2O) (H2 L is 2-{[2-(2-hy-droxy-3-meth-oxy-benzyl-idene-amino)-phenyl-imino]-meth-yl}-6-meth-oxy-phenol, C22H20N2O4) with yttrium acetate and potassium nitrate, respectively. In complex 2, the FeIII ions, which presumably arise through aerial oxidation from FeII, have a distorted square-pyramidal environment and are bridged by a μ2 oxo oxygen atom with an Fe-O-Fe angle of 137.97 (5)°. In complex (3) the environment around the FeIII ions is a distorted square pyramid. All four phenoxo oxygen atoms link the FeIII ions to a potassium atom (site symmetry 2), yielding two four-membered Fe/O/K/O rings. The K+ ion is linked also to four meth-oxy oxygen atoms.

PMID 42836228

Read full article →

+9996 more articles available with a free account

miriplatin hydrate (miriplatin hydrate / SMP 11355 / Miripla)

What is miriplatin hydrate?

Drug Profile

Therapeutic Indications

Related Research Articles

Hemihydrate phosphogypsum as a waste-derived sulfate source for low-carbon supersulfated cement: Hydration regulation and strength-normalized environmental performance.

Clinical efficacy and safety evaluation of dexmedetomidine hydrochloride nasal spray for sedation before examinations in children aged 2 to 6 years: protocol for a randomized controlled trial.

From Hydrogen Bond Disruption to Accelerated Polymerization: Atomic Mechanisms of Microwave-Accelerated C-A-S-H Gel Formation.

Effects of carbon dioxide hydrate cryotherapy on knee flexor muscle function recovery trajectory after muscle damage: a randomized controlled trial.

2,2'-(Ethane-1,2-di-yl)bis-[3-(pyridin-2-yl)imidazo[1,5-a]pyridin-2-ium] dichloride hexa-hydrate.

Structures of bimetallic FeIII-FeIII and trimetallic FeIII-K-FeIII complexes incorporating the deprotonated ligand N,N'-bis-(2-hy-droxy-3-methoxy-ben-zyl-idene)-1,2-phenyl-enedi-amine.

Ask about miriplatin hydrate